Metastatic BRAFV600E mutated colorectal cancer is associated with poor overall survival
and modest effectiveness to standard therapies. Furthermore, survival is influenced by the …

Background BRAF V600E mutations occur in fewer than 10% of all patients with metastatic
colorectal cancer (CRC) and arise from sessile serrated adenomas. Despite efficacy with …

A 30-year-old male presented with an obstructing leftsided colon tumor and extensive
peritoneal carcinomatosis. Palliative resection revealed mucinous adenocarcinoma of the …

Introduction: BRAFV600E metastatic colorectal cancer (CRC) is an aggressive tumor subset
with an approximate 8% incidence. In these patients, standard chemotherapy has limited …

The subset of metastatic colorectal adenocarcinomas that harbor BRAF V600E mutations
are aggressive tumors with significantly shortened survival and limited treatment options …

Abstract Background Non-V600E BRAF mutated colorectal cancer (CRC) is a rare disease
entity with specific clinical features. These tumors are less likely to have microsatellite …

Between 8% and 12% of patients with metastatic colorectal cancer (mCRC) harbor a BRAF-
V600E mutation in their tumors, which is associated with a poor response to standard …

BRAFV600-mutated colorectal cancer (CRC) accounts for 8% to 12% of all CRC diagnoses.
These tumors are often associated with specific patient features, including right-sided …

Two new treatments have recently become standard care for patients with metastatic
colorectal cancer (mCRC): encorafenib (BRAF inhibitor) associated with cetuximab (anti …

BRAF V600E is the driver mutation for approximately 10% of colorectal cancers and is found
more often in right-sided disease and older patients. 1, 2, 3 The presence of this mutation is …